The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -7.46 — distress zone — historically elevated failure riskWatch
Where the revenue comes from
Fiscal 2025, as KalVista Pharmaceuticals, Inc. reports it. History and quarterly detail are in the app.
- Research$5.0M
Leadership changes
From KalVista Pharmaceuticals, Inc.'s own filings, the day they're filed.
- Bilal Arif · Chief Operating Officer · appointmenteff. 2025-10-06
- Jebediah T. Ledell · Chief Operating Officer · appointmenteff. 2024-12-16
- KalVista Pharmaceuticals · Directors · departureeff. 2024-11-23
Latest filings
- 8-K · Company announcement2026-06-11
- 10-Q · Quarterly report2026-05-14
- 8-K · Company announcement2026-04-29
- 8-K · Company announcement2026-03-25
- 8-K · Company announcement2026-01-08
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about KalVista Pharmaceuticals, Inc., every answer cited to the official filings🔒
- The Intelligence Brief — added when KalVista Pharmaceuticals, Inc.'s brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.